Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis
Journal of Inherited Metabolic Disease · 2024
DOI: 10.1002/jimd.12773 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von Antonio Pisani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Fabry Disease, Registries, 1-Deoxynojirimycin, alpha-Galactosidase. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Fabry Registry data were analyzed among 83 agalsidase beta‐treated patients with Fabry disease who switched to migalastat. Outcomes (estimated glomerular filtration rate [eGFR], urine protein‐creatinine ratio [UPCR], plasma globotriaosylceramide [GL‐3], plasma globotriaosylsphingosine [lyso‐GL‐3], interventricular septal wall thickness [IVST], left posterior wall thickness [LPWT], left ventricular mass index [LVMI]) were assessed using linear mixed models to estimate annual change over time in the pre‐ and postswitch periods. eGFR decreased throughout both periods (preswitch: −0.85 mL/min/1.73 m 2 /year; postswitch: −1.96 mL/min/1.73 m 2 /year; both p < 0.0001), with steeper decline postswitch ( p pre/post = 0.01) in both classic and late‐onset patients. UPCR increased significantly postswitch ( p pre/post = 0.003) among classic patients and was stable in both periods among late‐onset patients. GL‐3 trajectories worsened postswitch across phenotypes ( p pre/post = 0.0005 classic, 0.02 late‐onset). LPWT was stable preswitch (0.07 mm/year, p = 0.25) and decreased postswitch (−0.51 mm/year, p = 0.0005; p pre/post = 0.0009), primarily among late‐onset patients. IVST and LVMI slopes varied significantly by phenotype. Among classic patients, IVST and LVMI were stable and decreasing, respectively preswitch and increasing postswitch ( p pre/post = 0.02 IVST, 0.01 LVMI). Among late‐onset patients, IVST significantly decreased postswitch ( p pre/post = 0.0003); LVMI was stable over time ( p pre/post = 0.89). Ultimately, eGFR and GL‐3 trajectories worsened postswitch across phenotypes, while UPCR and cardiac measures worsened among classic and stabilized/improved among late‐onset patients. These findings indicate variability in long‐term outcomes after switching from ERT to migalastat, underscoring the importance of careful monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, University of Naples Federico II, Naples, Italy.
- Navitas Data Sciences, Pottstown, Pennsylvania, USA.
- Sanofi, Cambridge, Massachusetts, USA.
- Division of Medicine, Turku University Hospital, Turku University, Turku, Finland.
- Jiménez Díaz Foundation University Hospital and IIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
- Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Förderung
- Sanofi
Zitieren
APA
Pisani, A., Wilson, K. M., Batista, J. L., Kantola, I., Ortiz, A., Politei, J., Al-Shaar, L., Maski, M., Crespo, A., Ponce, E., & Linhart, A. (2024). Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12773
Vancouver
Pisani A, Wilson KM, Batista JL, Kantola I, Ortiz A, Politei J, et al. Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12773
BibTeX
@article{Pisani2024,
author = {Pisani, Antonio and Wilson, Kathryn M and Batista, Julie L and Kantola, Ilkka and Ortiz, Alberto and Politei, Juan and Al-Shaar, Laila and Maski, Manish and Crespo, Ana and Ponce, Elvira and Linhart, Aleš},
title = {Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
doi = {10.1002/jimd.12773}
}
EUVIMED